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Serum homocysteine level and protein intake are related to risk of
microalbuminuria: The Hoorn Study.
Background. Microalbuminuria (MA) is a strong predictor of cardiovas-
cular disease, but its causes are incompletely understood. Hyperhomocys-
teinemia is a recently recognized risk factor for cardiovascular disease
independent of established risk factors. It is not known whether hyperho-
mocysteinemia is associated with MA, and thus could be a possible cause
of microalbuminuria.
Methods. We studied an age-, sex- and glucose-tolerance-stratified
random sample of a 50- to 75-year-old general Caucasian population (N 5
680). The urinary albumin-to-creatinine ratio (ACR) was measured in an
early morning spot urine sample. MA was defined as an ACR . 3.0
mg/mmol.
Results. The prevalence of MA was 4.3% (13 of 304) in subjects with
normal glucose tolerance, 9.2% (17 of 185) in impaired glucose tolerance
and 18.3% (30 of 164) in non-insulin-dependent diabetes mellitus
(NIDDM); it was 3.7% (15 of 402) in subjects without hypertension and
17.9% (45 of 251) in those with hypertension. After adjusting for age, sex,
glucose tolerance category, hypertension, dyslipidemia and smoking, the
odds ratio [OR; 95% confidence interval (95%CI)] for MA per 5
mmol/liter total homocysteine increment was 1.33 (1.08 to 1.63). Addi-
tional adjustment for HbA1c, waist-hip ratio, protein intake and serum
creatinine did not attenuate the association between MA and total
homocysteine. A 0.1 g/kg z day increment of protein intake was also
associated with an increased risk for MA after adjustment for age, sex,
classical risk factors and serum total homocysteine [OR (95% CI); 1.20
(1.08 to 1.32)].
Conclusion. Both hyperhomocysteinemia and protein intake are related
to microalbuminuria independent of NIDDM and hypertension. Hyper-
homocysteinemia may partly explain the link between MA and increased
risk of cardiovascular disease.
A slightly elevated urinary albumin excretion rate, so-
called microalbuminuria, is a strong predictor of cardiovas-
cular morbidity and mortality in both non-insulin-depen-
dent diabetes mellitus (NIDDM) and non-diabetic
individuals [1, 2]. The increased risk of cardiovascular
disease in individuals with microalbuminuria is only partly
due to a higher prevalence of established risk factors such
as diabetes, hypertension, smoking and dyslipidemia. The
pathophysiological basis of the association between mi-
croalbuminuria and cardiovascular disease remains to be
elucidated. The most widely held view is that microalbu-
minuria indicates underlying generalized vascular, possibly
endothelial, dysfunction [3, 4]. Therefore, microalbumin-
uria and atherothrombotic disease may have certain patho-
genetic mechanisms in common.
Hyperhomocysteinemia is a recently recognized risk fac-
tor for cardiovascular disease independent of established
risk factors [5, 6]. It is not known whether hyperhomocys-
teinemia is associated with and thus a possible cause of
microalbuminuria. Therefore, we investigated this issue in
a 50- to 75 year-old general population, an age range in
which both hyperhomocysteinemia [7, 8] and microalbu-
minuria [2] are known to be relatively common.
A high protein intake may increase the risk of developing
microalbuminuria [9, 10] and conceivably may also increase
serum total homocysteine (tHcy) levels [11]. It is thus a
potential confounder of the relationship, if any, between
hyperhomocysteinemia and microalbuminuria. We there-
fore specifically examined the relationships between pro-
tein intake, serum total homocysteine, and presence of
microalbuminuria.
METHODS
The Hoorn Study is a cross-sectional survey of glucose
tolerance and other cardiovascular risk factors in a 50- to
75-year-old general Caucasian population conducted from
1989 to 1992. A random sample of all men and women aged
50 to 75 years was drawn from the municipal population
registry office of Hoorn (the Netherlands); 2,484 subjects
participated (response rate 71%). The presence of mi-
croalbuminuria was investigated (as detailed below) in an
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age-, sex- and glucose-tolerance-stratified random sub-
sample (N 5 680, response rate 96%), which was con-
structed by means of a second sampling, as described
previously in detail [12]. The Hoorn Study was approved by
the Ethical Review Committee of the University Hospital
Vrije Universiteit Amsterdam. Informed consent was ob-
tained from all participants.
An early morning first voided spot urine sample was
collected. Urinary albumin was measured by rate nephe-
lometry (Array Protein System; Beckman, Ireland) with a
threshold of 6.2 mg/liter and intra- and inter-assay coeffi-
cients of variation of # 5% and # 8%, respectively. Urinary
creatinine was measured by a modified Jaffe´ method. The
urinary albumin-to-creatinine ratio (ACR) was calculated.
For those urine samples with an albumin concentration less
than the threshold, the value 6.2 was taken to calculate the
ACR. An ACR # 3.0 mg/mmol was defined as normoalbu-
minuric, an ACR .3.0 mg/mmol as (micro)albuminuric
and an ACR .30.0 mg/mmol as macroalbuminuric. [An
ACR of 3 to 30 mg/mmol is approximately equivalent to an
albumin excretion rate (AER) of 30 to 300 mg/24 hours]
[13, 14]. We also considered a lower cut-off value (ACR .
2.0 mg/mmol) to define (micro)albuminuria. To investigate
the reproducibility of the ACR, we collected a second urine
sample from a representative sample of 185 subjects in
similar fashion. Of all subjects (N 5 680), 24 urine samples
were missing. In addition, we excluded three subjects from
further analyses because no serum was available for homo-
cysteine measurement. Thus, analyses were performed on
653 subjects, of whom 185 had an ACR on the basis of the
mean of two measurements. By utilizing the available
duplicate measurements we reduced the effect of possible
misclassification of (micro)albuminuric subjects. Finally,
the presence of leukocytes was evaluated by microscopy
and scored as positive (.5 leukocytes per high-power field)
or negative; a microscopic report was missing in 60 of the
available urine samples.
Measurement of serum total homocysteine
Fasting blood samples were centrifuged within one hour
following collection. Serum was stored at 220°C for six
years. There is good evidence that serum tHcy levels are
stable for 10 years or more [15]. Serum total (free plus
protein bound) homocysteine level was measured by using
tri-n-butylphosphine as the reducing agent and ammonium
7-fluorobenzo-2-oxa-1,3-diazole-4-sulphonate as the thiol-
specific fluorochromophore, followed by HPLC with fluo-
rescence detection [16]. The intra- and interassay coeffi-
cients are 2.1% and 5.1%.
Other procedures
We measured fasting serum total cholesterol, high den-
sity lipoprotein (HDL)-cholesterol and triglycerides by
enzymatic techniques (Boehringer-Mannheim, Mannheim,
Germany). The Friedewald formula was used to calculate
the low density lipoprotein (LDL) cholesterol concentra-
tion, except in subjects with serum triglyceride levels .8.0
mmol/liter (N 5 3) [17]. Serum creatinine was measured by
the modified Jaffe´ method. The creatinine clearance was
calculated from serum creatinine, using the Cockcroft and
Gault formula [18]. Normal renal function and mild and
moderate renal failure were defined as creatinine clearance
.80, 51 to 80 and 24 to 50 ml/min, respectively. (There
were no subjects with creatinine clearance ,24 ml/min.)
Immunospecific insulin was measured in serum by a dou-
ble-antibody radioimmunoassay (lot SP21; Linco Research,
St. Louis, MO, USA). The inter-assay coefficient of varia-
tion was 6%. The lower limit of sensitivity was 12 pmol/
liter. Hypercholesterolemia was defined as total choles-
terol $ 6.5 mmol/liter and/or the current use of cholesterol-
lowering medication. Dyslipidemia was defined as levels of
HDL-cholesterol in the lowest (#1.02 mmol/liter) and/or
levels of triglycerides in the highest quartile ($2.10 mmol/
liter). Hypertension was defined as a blood pressure $ 160
mm Hg systolic and/or $ 95 mm Hg diastolic and/or the
current use of antihypertensive medication. Impaired glu-
cose tolerance (IGT) and NIDDM were defined according
to the WHO criteria (1985) [19]. Subjects were classified as
either nonsmokers or current smokers. The waist-hip ratio
was measured as previously described [12]. Body mass
index was calculated as weight divided by height squared
(kg/m2). Information on protein (animal and vegetable)
intake was obtained by a self-administered validated semi-
quantitative food frequency questionnaire (N 5 638) [20].
All laboratory measurements were carried out by techni-
cians unaware of the subjects’ history of cardiovascular
disease and glucose tolerance status.
Statistical analysis
Variables are presented as mean 6 SD, number (percent-
age of the total) or, in case of skewed distribution, median
and interquartile range (IQR) or geometric mean. Differ-
ences between subjects with normo- and those with (mi-
cro)albuminuria were tested with Student’s t or Wilcoxon’s
rank sum test for continuous variables and Pearson’s
chi-square test for frequency measures. Associations of
cardiovascular risk factors with serum tHcy level (logarith-
mically transformed) were studied by calculating Pearson’s
correlation coefficients. The kappa coefficient was calcu-
lated to estimate the agreement of the ACR .3.0 mg/mmol
between two measurements.
We performed logistic regression analyses to study the
association of serum tHcy with (micro)albuminuria. We
calculated odds ratios (ORs) and 95% confidence intervals
(CIs) per 5 mmol/liter (about 1 SD) increment of serum
tHcy, assuming a linear logistic relationship between ho-
mocysteine and risk of (micro)albuminuria. We used mul-
tiple logistic regression analysis to control for age, sex,
glucose tolerance category, hypertension, current smoking
and dyslipidemia. To control for confounding as thoroughly
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as possible, we used, in all analyses, four categories of
glucose tolerance: normal glucose tolerance (NGT), IGT,
newly detected and known NIDDM. We also tested models
that in addition included HbA1c, waist-hip ratio (or BMI),
protein intake (g/kg z day), serum creatinine or creatinine
clearance and/or fasting insulin level. To evaluate a possi-
ble modifying role of other risk factors, we repeated the
previous analyses in strata of sex, diabetes, hypertension,
dyslipidemia, hypercholesterolemia and current smoking.
In addition, we investigated product terms in the logistic
regression models. We also evaluated a possible dose-
response relation by calculating ORs for (micro)albumin-
uria for several ranges of homocysteine concentrations with
values of serum tHcy equal to or less than 10 mmol/liter as
the reference category. By using this procedure we evaded
assumptions about linearity.
Finally, the associations between animal and vegetable
protein intake and (micro)albuminuria were investigated.
We evaluated a possible modifying role of hypertension
and glycemic control (HbA1c). A possible dose-response
relation was investigated by calculating ORs for (mi-
cro)albuminuria for several ranges of daily protein intake
with values of total protein intake equal to or less than 0.75
g/kg z day as the reference category. All reported P values
are two-tailed. All analyses were performed with SPSS for
Windows 7.5.2.
RESULTS
The prevalence of (micro)albuminuria was 9.2% (60 of
653). The kappa coefficient (95% CI) of two urine sample
measurements was 0.53 (0.28 to 0.77) for ACR .3.0
mg/mmol, indicating a moderate agreement. As compared
to subjects with normoalbuminuria, those with (micro)albu-
minuria were older, had a higher waist-hip ratio and systolic
and diastolic blood pressures, more often had NIDDM and
moderate renal failure, and had higher serum levels of
creatinine and tHcy (Table 1). The prevalence of (mi-
cro)albuminuria was 4.3% (13 of 304) in subjects with
NGT, 9.2% (17 of 185) in IGT and 18.3% (30 of 164) in
NIDDM; it was 3.7% (15 of 402) in subjects without
Table 1. Characteristics of the subjects
Normoalbuminuria
ACR # 3.0 mg/mmol
N 5 593
(Micro)albuminuria
ACR . 3.0 mg/mmol
N 5 60 P valuea
Men % 48.1 45.0 0.7
Age years 63.9 (7.1) 67.3 (6.7) , 0.0001
Body mass index kg/m2 27.1 (3.7) 28.2 (6.0) 0.2
Waist-hip ratio 0.91 (0.09) 0.94 (0.07) 0.003
Blood pressure mm Hg
Systolic 138 (19) 154 (21) , 0.0001
Diastolic 82 (10) 87 (13) , 0.0001
Hypertension % 34.7 75.0 , 0.0001
Use of antihypertensives %
Angiotensin-converting enzyme inhibitor 4.7 10.0 0.09
Other 19.7 41.7 , 0.0001
Impaired glucose tolerance % 28.3 28.3 1.0
Non-insulin-dependent diabetes mellitus % 22.6 50.0 , 0.0001
Current smoker % 28.9 25.4 0.6
Protein intake g/kg z day
total 0.97 (0.27) 1.04 (0.39) 0.2
animal 0.68 (0.22) 0.73 (0.29) 0.1
vegetable 0.30 (0.11) 0.31 (0.17) 0.3
HbA1c % of hemoglobin 5.8 (1.2) 6.5 (1.7) 0.002
Fasting insulin pmol/liter 84 (63–114) 90 (70–143) 0.007
Total cholesterol mmol/liter 6.7 (1.2) 6.5 (1.2) 0.3
LDL cholesterol mmol/liter 4.6 (1.1) 4.3 (1.0) 0.06
HDL cholesterol mmol/liter 1.3 (0.4) 1.2 (0.3) 0.1
Triglycerides mmol/liter 1.5 (1.1–2.1) 1.5 (1.1–2.8) 0.1
Dyslipidemia % 38.0 48.3 0.1
Creatinine mmol/liter 91 (16) 104 (35) 0.005
Creatinine clearanceb ml/min 75 (18) 67 (20) 0.001
Mild renal failurec % 58.7 56.7 0.8
Moderate renal failured % 5.6 18.3 , 0.0001
Total homocysteine mmol/liter 11.4 (9.4–14.2) 12.7 (10.0–15.5) 0.05
Data are presented as mean (standard deviation), percentage of the total or median (interquartile range). ACR is the albumin-to-creatinine ratio.
Dyslipidemia was defined as levels of HDL-cholesterol in the lowest (#1.02 mmol/liter) and/or levels of triglycerides in the highest quartile ($2.10
mmol/liter).
a Tested with Student’s t-test or Wilcoxon’s rank sum test for continuous variables and Pearson’s chi-square test for frequencies
b Calculated from serum creatinine using the Cockcroft and Gault formula
c Creatinine clearance 51 to 80 ml/min
d Creatinine clearance 24 to 50 ml/min
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hypertension and 17.9% (45 of 251) in those with hyper-
tension. Figure 1 shows the prevalence of (micro)albumin-
uria according to the absence or presence of hyperhomo-
cysteinemia (.18 mmol/liter) in subjects without or with
hypertension and/or diabetes mellitus. We chose this cut-
off value since risk of (micro)albuminuria increased mark-
edly above this value (Fig. 2).
The median serum tHcy level was 12.2 mmol/liter (IQR,
10.0 to 15.4) in men and 11.0 mmol/liter (IQR, 9.1 to 13.6)
in women. Serum tHcy levels correlated with age (r 5 0.20;
P , 0.0001), serum creatinine (r 5 0.41; P , 0.0001),
systolic blood pressure (r 5 0.11; P 5 0.004), waist-hip ratio
(r 5 0.10; P 5 0.008), fasting insulin (r 5 0.08; P , 0.05),
and inversely with creatinine clearance (r 5 20.3; P 5 0.01)
and animal protein intake (r 5 20.16; P , 0.0001), but not
with vegetable protein intake (r 5 20.1, P 5 0.1), BMI (r 5
20.05; P 5 0.3), diastolic blood pressure (r 5 0.04; P 5
0.3), serum total cholesterol (r 5 0.01; P 5 0.8), HDL
cholesterol (r 5 20.07; P 5 0.06) or HbA1c (r 5 20.02; P 5
0.6). The geometric mean serum tHcy level in subjects with
moderate and mild renal failure and those with normal
renal function were 14.7, 12.4 and 10.6 mmol/liter (P for
trend , 0.0001).
A 5 mmol/liter increment of serum tHcy was associated
with an increased risk of (micro)albuminuria independent
of classical risk factors (Table 2, model 1; Fig. 1). Addi-
tional adjustment for serum creatinine (Table 2, model 2)
or creatinine clearance did not materially change the ORs,
nor did inclusion of total cholesterol, triglycerides, HDL
and LDL cholesterol, fasting insulin, systolic blood pres-
sure and/or BMI in the model (data not shown). Exclusion
of subjects (N 5 7) who had an ACR .3.0 mg/mmol based
on an albumin concentration of 6.2 mg/liter (5 threshold)
yielded similar results (data not shown). If (micro)albumin-
uria was defined as an ACR .2.0 mg/mmol, the ORs (95%
CIs) for models 1 and 2 were 1.27 (1.04 to 1.54) and 1.25
(1.02 to 1.55).
Macroalbuminuria was present in seven subjects. After
adjustment for age and sex, the OR (95% CI) for mac-
roalbuminuria per 5 mmol/liter increment serum tHcy was
1.33 (1.02 to 1.72). After exclusion of the seven macroalbu-
minuric subjects and adjustment for age, sex and classical
risk factors, the OR for microalbuminuria (ACR: 3230
mg/mmol) per 5 mmol/liter increment serum tHcy was 1.28
(1.01 to 1.61). Since the strength of the association between
micro- or macroalbuminuria and serum tHcy did not differ
substantially, we pooled all subjects with an ACR .3.0
mg/mmol.
Angiotensin-converting enzyme inhibitors and other an-
tihypertensives can reduce the urinary albumin excretion.
The geometric means of tHcy of subjects who did not or did
use an angiotensin-converting enzyme inhibitor were 11.8
and 12.5 mmol/liter, respectively (P 5 0.5). Adjustment for
use of angiotensin-converting enzyme inhibitors (yes/no) in
addition to classical risk factors (model 1 in Table 2) did
not materially change the association between tHcy and
(micro)albuminuria [OR (95% CI) 1.32 (1.07 to 1.62)].
Adjustment for use of antihypertensives (yes/no) yielded
similar results. The geometric means of tHcy of subjects
without or with leukocyturia were 11.9 and 12.4 mmol/liter,
Fig. 1. Prevalence of (micro)albuminuria according to absence or pres-
ence of hyperhomocysteinemia (>18.0 mmol/liter) in subjects without or
with hypertension and/or diabetes. Symbols are: (M) homocysteine lev-
els # 18 mmol/liter; (u) homocysteine levels . 18 mmol/liter. Risk of
(micro)albuminuria increases markedly above this cut-off value (see Fig.
2). The error bars represent the upper half of the 95% confidence
intervals. Number of subjects with (micro)albuminuria of each subgroup
are presented below the bars.
Fig. 2. Odds ratio for (micro)albuminuria according to serum total
homocysteine level adjusted for age, sex, impaired glucose tolerance/
diabetes mellitus, hypertension and protein intake. The reference cate-
gory was serum total homocysteine values equal to or less than 10
mmol/liter. The percentages of the population under study for each serum
total homocysteine range are presented. Error bars represent the upper
half of the 95% confidence intervals. *P , 0.05, significantly different from
the reference category. P for trend 5 0.06. (Note: A logarithmic scale was
used since the odds ratio is a multiplicative measure of association, that is,
equal differences on the logarithmic scale correspond to equal ratios
between the odds ratios.)
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respectively (P 5 0.2). Additional adjustment for leukocy-
turia [that is, yes/no; present in 15.7% (93 of 594) of the
subjects] also yielded similar results [OR (95% CI) 1.28
(1.01 to 1.61)], as did adjustment for the presence of
cardiovascular disease (10.7%: 65 of 607), as defined
elsewhere [8] OR 1.25 (1.05 to 1.50).
We evaluated possible modification by other risk factors
of the effect of tHcy on risk of (micro)albuminuria and did
not observe substantial differences among the following
strata: sex, diabetes, hypertension, dyslipidemia, hypercho-
lesterolemia and current smoking (data not shown). In
addition, interaction terms between serum tHcy and these
risk factors were not significant. Risk of (micro)albumin-
uria increased with increasing serum tHcy levels (Fig. 2). In
none of the above analyses did log-transformation of tHcy
result in a better fit (data not shown). Finally, although
(micro)albuminuria is usually considered as a dichotomous
variable, we also performed multiple linear regression
analysis with log-transformed ACR as the (continuous)
dependent variable. After adjustment for age, sex, diabetes,
hypertension and renal function, ACR showed a highly
significant association with tHcy (P , 0.0001).
The present study was too small to adequately investigate
whether the relationship between microalbuminuria and
cardiovascular disease can be explained to some extent by
hyperhomocysteinemia (data not shown).
Protein intake correlated with creatinine clearance (r 5
0.2; P , 0.01). An 0.1 g/kg z day increment of the daily
animal or vegetable protein intake was associated, after
adjustment for age, sex, classical risk factors and serum
tHcy, with an increased risk of (micro)albuminuria [OR
(95%CI); 1.22 (1.08 to 1.39) and 1.32 (1.07 to 1.62)]. Since
these ORs did not differ substantially, we calculated the
strength of the association between total protein intake and
(micro)albuminuria to be OR 1.20 (1.08 to 1.32). After
exclusion of known diabetic patients the OR was 1.18 (1.04 to
1.33). There was no evidence of interaction between hyper-
tension or glycemic control and protein intake with regard to
risk of (micro)albuminuria. Risk of (micro)albuminuria in-
creased with increasing daily total protein intake (Fig. 3).
DISCUSSION
This is, to our knowledge, the first population-based
study unequivocally showing that serum total homocysteine
is positively associated with the presence of microalbumin-
uria independent of major determinants, that is, diabetes
mellitus, hypertension, protein intake and renal function.
For each 5 mmol/liter (about 1 SD) increase in serum tHcy
level, the risk of microalbuminuria being present increased
by about 30%. The result of the present study is in line with
a few studies that reported a positive association between
albuminuria and tHcy level [21, 22], but contradicts other
studies [23, 24]. However, none of these studies adjusted
for all major determinants of microalbuminuria and some
[23, 24] used relatively small populations.
We chose two different approaches to investigate the
nature of the association between tHcy and microalbumin-
uria. First, we analyzed the association with tHcy as a
continuous variable, since there is evidence that the asso-
ciation of tHcy with risk of cardiovascular disease is graded
[6, 25]. Second, we evaluated a possible dose-response
relationship between microalbuminuria and several ranges
of tHcy. Inspection of Figure 2 suggests that there might be
a threshold (at 18 mmol/liter) above which an increased risk
of microalbuminuria exists. Obviously the present study is
not large enough to solve the question of whether the
association between microalbuminuria and tHcy is graded
or has a certain threshold.
Microalbuminuria is thought to be caused by increased
glomerular albumin filtration as a result of decreased
glomerular charge selectivity, size selectivity and/or in-
creased intraglomerular pressure [26, 27], which regulation
is affected by renal endothelial and mesangial cell function
Table 2. Odds ratios (ORs; 95% confidence intervals) for
(micro)albuminuria per 5 mmol/liter increment of serum total
homocysteine
(Micro)albuminuria
ACR mg/mmol Cases
Crude
Age- &
sex-adjusted Model 1 Model 2
OR
.3.0 60 1.30 1.30 1.33 1.28
(1.09–1.54) (1.08–1.56) (1.08–1.63) (1.03–1.59)
Model 1 was adjusted for age, sex, glucose tolerance category, hyper-
tension (yes/no), current smoking (yes/no) and dyslipidemia (yes/no).
Model 2 was model 1 1 additional adjustment for protein intake and
serum creatinine. Abbreviation ACR is albumin-to-creatinine ratio.
Fig. 3. Odds ratio for (micro)albuminuria according to total protein
intake adjusted for age, sex, impaired glucose tolerance/diabetes mellitus,
hypertension and total homocysteine. The reference category was total
protein intake 0.75 to 1.00 g/kg z day. Percentages of the population under
study for each total protein intake range are presented. Error bars
represent the lower or upper half of the 95% confidence intervals. *P ,
0.05, significantly different from the reference category. P for trend 5
0.001.
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[28, 29]. Mesangial cells have some properties in common
with vascular smooth muscle cells [29]. Hyperhomocys-
teinemia may induce dysfunction of the vascular endothe-
lium [30] and increase proliferation of vascular smooth
muscle cells [31], possibly by increasing oxidative stress
[32]. Therefore, it is conceivable that hyperhomocysteine-
mia is causally related to microalbuminuria through
changes in renal endothelial and mesangial cell function
and might thus be one of the factors that link the presence
of microalbuminuria to an increased risk of atherothrom-
botic disease [1, 2].
We considered three sources of disease misclassification
that may have resulted in bias of the association between
hyperhomocysteinemia and persistent microalbuminuria.
First, of the majority (72%) of subjects we collected only
one urine sample to assess microalbuminuria. Repeated
measurements would have improved the accuracy of clas-
sification of persistent microalbuminuria since there is a
considerable day-to-day intra-individual variability of albu-
min excretion [33, 34]. Second, approximately 24% of all
subjects classified as normoalbuminuric used antihyperten-
sive medication. Antihypertensives, especially angiotensin-
converting enzyme inhibitors, are likely to decrease urinary
albumin excretion [35]. Finally, the presence of leukocytu-
ria, which, insofar as it reflects urinary tract infection, might
increase urinary albumin excretion. In all three cases, the
possible disease misclassification was non-differential with
regard to serum tHcy level. In general, non-differential
disease misclassification would likely bias the findings to-
ward effect attenuation (that is, underestimation of the
strength of the association between hyperhomocysteinemia
and microalbuminuria) [36].
The present study confirms and extends previous obser-
vations that tHcy and creatinine clearance are strongly
associated [22]. An impaired renal function causes a sub-
stantial increase in the half-life of tHcy explained by a
reduction in total body clearance [37, 38]. In addition, an
impaired renal function is a risk factor for microalbumin-
uria. As the association between tHcy and microalbumin-
uria did not materially change after adjustment for serum
creatinine or creatinine clearance (Table 2), we consider it
improbable that impaired renal function confounded the
association between tHcy and the presence of microalbu-
minuria. Finally, we cannot fully exclude that proximal
tubular dysfunction in the presence of a normal glomerular
filtration rate (GFR) results in both decreased albumin
reabsorption (and thus microalbuminuria) and impaired
tHcy metabolism, but this appears unlikely.
A poor folate, vitamin B12 and/or vitamin B6 status can
increase serum tHcy level [39]. Since we did not assess B
vitamins and the present study is cross-sectional, we cannot
rule out the possibility that low vitamin B levels may
increase urinary albumin excretion or that microalbumin-
uria per se can raise serum tHcy levels, although this
appears biologically implausible. Even though in an elderly
population hyperhomocysteinemia, microalbuminuria and
vitamin B deficiency frequently coexist, this does not ex-
plain the positive association we found between serum tHcy
and microalbuminuria. Only when vitamin B deficiency
would be the cause of both microalbuminuria and hyper-
homocysteinemia, which seems unlikely with respect to
microalbuminuria, could vitamin B deficiency have been a
confounder of the association between tHcy and mi-
croalbuminuria. Serum tHcy levels can be lowered with an
increased intake of B vitamins, particularly folate. A ran-
domized clinical trial could thus support the hypothesis that
tHcy might be a causal factor of microalbuminuria. Al-
though the dose-response relationship we found between
hyperhomocysteinemia and microalbuminuria does not
necessarily support a causal relationship between tHcy and
microalbuminuria, departures from expected biologic gra-
dients do provide evidence against causation.
We investigated whether dietary protein intake con-
founded the association between tHcy and microalbumin-
uria. We found that dietary protein intake did not explain
the relationship between tHcy and microalbuminuria.
However, we did observe an increased risk of microalbu-
minuria with increasing consumption of total protein inde-
pendent of serum tHcy levels. This observation is consistent
with some [9, 40] but not all studies [41]. A high protein
intake may result in an increased GFR and renal workload
and therefore aggravate proteinuria [42]. In addition, it has
previously been demonstrated that an animal compared to
a vegetable protein diet, independently of the daily amount
of protein intake, results in a higher GFR and urinary
albumin excretion [43].
In the present study additional adjustment for animal or
total protein intake, if anything, strengthened the associa-
tion between serum tHcy with regard to risk of microalbu-
minuria. Taken together, it appears unlikely that hyperho-
mocysteinemia and high animal protein intake share a
common causal pathway with regard to risk of microalbu-
minuria. Therefore, both appear important determinants of
microalbuminuria.
We conclude that both hyperhomocysteinemia and a
high protein intake are related to microalbuminuria inde-
pendent of non-insulin-dependent diabetes mellitus and
hypertension. Hyperhomocysteinemia may partly explain
the link between microalbuminuria and increased risk of
cardiovascular disease.
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